Arrowstreet Capital, Limited Partnership Puma Biotechnology, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $114 Billion
- Q2 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 92,174 shares of PBYI stock, worth $273,756. This represents 0.0% of its overall portfolio holdings.
Number of Shares
92,174
Previous 230,425
60.0%
Holding current value
$273,756
Previous $1.22 Million
75.43%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding PBYI
# of Institutions
98Shares Held
29.3MCall Options Held
73.5KPut Options Held
18.5K-
Vanguard Group Inc Valley Forge, PA3.64MShares$10.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$10.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.16MShares$9.39 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$9.1 Million0.59% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$5.85 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $135M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...